Loading
A phase 3 trial of 2-doses Group among 9-14 years in cervical cancer and vaginal cancer, run by Shanghai Bovax Biotechnology Co., Ltd., now recruiting.
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years is a phase 3 interventional study registered as NCT05027776 by Shanghai Bovax Biotechnology Co., Ltd., with 1348 participants planned, started 2021-09-15 and due to reach its primary completion in 2023-11-22. Interventions recorded: 2-doses Group among 9-14 years, 3-doses Group among 9-19 years and 3-doses Group among 20-26 years.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Vaginal squamous cell carcinoma (HPV-associated), Vaginal cancer and the tag pipeline.
Shares Shanghai Bovax Biotechnology and the tag pipeline.
Shares Vaginal cancer and the tag pipeline.
Shares Cervical cancer and the tag pipeline.
Shares Cervical cancer and the tag pipeline.
Shares Cervical cancer and the tag pipeline.
Shares Cervical cancer and the tag pipeline.
Shares Cervical cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/